Link: https://links.sgx.com/1.0.0/corporate-announcements/85TNXYDWXB7S8MAV/1ca0bc1fa95636070eb4067c4d6402ed51ab9651619fea2189625e872c2a7851

Summary:

• Revenue reached US$12.2 million, with net profit at US$0.5 million, reflecting resilient performance during a challenging year of regulatory shifts and market changes.

• Proposed first-ever dividend since IPO, signaling financial discipline and commitment to shareholder value.

• Expanded regionally with major partnership in Malaysia (AP Bioresources) and exclusive drug delivery platform (ODS) agreement with Thailand’s GPO for Sildenafil.

• Product portfolio includes proprietary oral disintegrating strips (ODS), N95 respirators and masks, B2C pet health solutions (“furlife”), and comprehensive medical supplies.

• Core markets include Canada, Japan, Hong Kong, Singapore, and others; diversified revenue streams through pharmaceutical wholesale, masks, and medical device drop-shipment.

• Focused on innovation and R&D; launched new platforms for human and animal healthcare, and enhanced supply chain infrastructure, including cold chain warehouse.

• Achieved multiple international certifications, including 14 FDA clearances, NIOSH, ISO13485, and Halal for medical devices.

• Sustainability efforts span governance, climate impact, diversity (35% target for female workforce), zero-discrimination policy, and zero-tolerance anti-corruption.

• Engaged stakeholders and pursued ESG goals under Global Reporting Initiative and TCFD standards, aligning strategy with UN Sustainable Development Goals.

• Board and management emphasize strong governance, stakeholder engagement, transparent reporting, and efficient risk management for future growth and responsible healthcare solutions.